Protein Attributes-Based Predictive Tool in a Down Syndrome Mouse Model: A Machine Learning Approach
暂无分享,去创建一个
Brígida Mónica Faria | Cláudia Ribeiro-Machado | Sara Costa Silva | Sara Aguiar | S. C. Silva | B. M. Faria | C. Ribeiro-Machado | Sara Aguiar
[1] B. Tycko,et al. Mouse-based genetic modeling and analysis of Down syndrome. , 2016, British medical bulletin.
[2] R. Neve,et al. NMDA receptor subunit composition controls dendritogenesis of hippocampal neurons through CAMKII, CREB‐P, and H3K27ac , 2017, Journal of cellular physiology.
[3] Y. Hérault,et al. Rodent models in Down syndrome research: impact and future opportunities , 2017, Disease Models & Mechanisms.
[4] B. Tycko,et al. Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome , 2015, Neurobiology of Aging.
[5] E. Valdizán,et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. , 2010, Journal of Alzheimer's disease : JAD.
[6] Bahram Goliaei,et al. Prediction of lung tumor types based on protein attributes by machine learning algorithms , 2013, SpringerPlus.
[7] K. Cios,et al. Self-Organizing Feature Maps Identify Proteins Critical to Learning in a Mouse Model of Down Syndrome , 2015, PloS one.
[8] Cao D. Nguyen,et al. Machine Learning Methods Predict Locomotor Response to MK-801 in Mouse Models of Down Syndrome , 2011, Journal of neurogenetics.
[9] K. Gardiner. Molecular basis of pharmacotherapies for cognition in Down syndrome. , 2010, Trends in pharmacological sciences.
[10] M. Atalay,et al. Oxidant production and SOD1 protein expression in single skeletal myofibers from Down syndrome mice , 2017, Redox biology.
[11] Alberto C. S. Costa,et al. On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome , 2011, Developmental Neuroscience.
[12] Alberto C. S. Costa,et al. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. , 2011, Learning & memory.
[13] M. Kazemi,et al. Down Syndrome: Current Status, Challenges and Future Perspectives , 2016, International journal of molecular and cellular medicine.
[14] Osman Erogul,et al. Down Syndrome Diagnosis Based on Gabor Wavelet Transform , 2012, Journal of Medical Systems.
[15] Shalu Jain,et al. “Down syndrome: an insight of the disease” , 2015, Journal of Biomedical Science.
[16] D. B. Victorino,et al. Pharmacokinetic Properties of Memantine after a Single Intraperitoneal Administration and Multiple Oral Doses in Euploid Mice and in the Ts65Dn Mouse Model of Down's Syndrome , 2017, Basic & clinical pharmacology & toxicology.
[17] Mansour Ebrahimi,et al. Classification of Lung Cancer Tumors Based on Structural and Physicochemical Properties of Proteins by Bioinformatics Models , 2012, PloS one.
[18] Xinying Xu,et al. Using Supervised Machine Learning Algorithms to Screen Down Syndrome and Identify the Critical Protein Factors , 2017 .
[19] A. Granholm,et al. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome , 2011, Behavioural Brain Research.
[20] A. Ranjitha Dhanasekaran,et al. Protein Dynamics Associated with Failed and Rescued Learning in the Ts65Dn Mouse Model of Down Syndrome , 2015, PloS one.
[21] Marius George Linguraru,et al. Automated down syndrome detection using facial photographs , 2013, 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).